CLEC10A and glioblastoma: Finally, could HML-2 antigens (e.g, GAG, POL, ENV, LTR5Hs) that are expressed in GBM cells, but not in normal brain, be targeted by immunotherapeutic approaches, perhaps in combination with ICB?